Complete Filing Data
BridgeBio Oncology Therapeutics, Inc. reported Stockholders Equity of $411.10 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean BridgeBio Oncology Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income Loss | -$134.0M | -$74.3M | -$41.7K |
| Operating Income Loss | -$145.8M | -$80.9M | -$41.7K |
| General And Administrative Expense | $24.6M | $7.8M | $41.7K |
| Nonoperating Income Expense | $11.8M | $6.6M | |
| Investment Banking Revenue | $6.2K | ||
| Research And Development Expense | $121.2M | $73.1M | |
| Other Nonoperating Income Expense | -$35.0K | $0.00 | |
| Operating Expenses | $145.8M | $80.9M | |
| Comprehensive Income Net Of Tax | -$134.4M | -$73.9M | |
| Research And Development Expenses Include Related Party |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income Loss | -$44.8M | -$28.4M | -$22.1M | -$17.3M | -$21.8M | -$15.4M |
| Operating Income Loss | -$49.2M | -$1.1M | -$2.4M | -$19.7M | -$152.3K | -$66.7K |
| General And Administrative Expense | $14.1M | $1.1M | $2.4M | $1.8M | $152.3K | $66.7K |
| Nonoperating Income Expense | $4.4M | $2.0M | $1.9M | $2.3M | $2.4M | $1.2M |
| Investment Banking Revenue | $1.2K | $2.4K | $3.0K | |||
| Research And Development Expense | $35.1M | $17.9M | ||||
| Other Nonoperating Income Expense | -$30.0K | $0.00 | ||||
| Operating Expenses | $49.2M | $19.7M | ||||
| Comprehensive Income Net Of Tax | -$44.8M | -$16.5M | ||||
| Research And Development Expenses Include Related Party | $153.0K | $636.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $411.1M | -$178.6M | -$115.6M | -$21.9K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $373.8M | $31.0M | $250.0K | |
| Retained Earnings Accumulated Deficit | -$356.6M | -$222.5M | -$88.6K | |
| Liabilities Current | $35.0M | $19.6M | $396.5K | |
| Liabilities And Stockholders Equity | $448.4M | $164.3M | $332.9K | |
| Liabilities | $37.3M | $19.6M | $396.5K | |
| Assets | $448.4M | $164.3M | $332.9K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $342.8M | $30.7M | ||
| Temporary Equity Accretion To Redemption Value | ||||
| Assets Current | $432.4M | $158.7M | ||
| Accrued Liabilities Current | $15.0K | |||
| Assets Held In Trust Noncurrent | ||||
| Deferred Underwriting Fee | ||||
| Noncash Accrued Offering Costs Adjustment | $81.0K | |||
| Deferred Offering Costs Paid By Sponsor Through Promissory Note | $139.8K | |||
| Repayments Of Related Party Debt | $209.9K | |||
| Paymentto Acquire Investmentof Cash In Trust Account | $184.0M | |||
| Prepaid Expense And Other Assets Current | $6.6M | $3.0M | ||
| Notes Payable Current | $534.0K | $483.0K | $70.1K | |
| Marketable Securities Unrealized Gain Loss | -$332.0K | $348.0K | ||
| Accrued Offering Costs Current | $311.4K | |||
| Temporary Equity Accretion To Redemption Value Adjustment | $16.6M | |||
| Deferred Costs | $332.9K | |||
| Common Stock Value | $8.0K | $0.00 | ||
| Cash And Cash Equivalents At Carrying Value | $373.7M | $30.9M | ||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $2.7M | $0.00 | ||
| Restricted Cash Noncurrent | $132.0K | $132.0K | ||
| Property Plant And Equipment Net | $956.0K | $490.0K | ||
| Participation Right Liability |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $446.7M | -$227.7M | -$200.0M | -$159.2M | -$143.4M | -$128.9M | -$21.9K | -$21.9K | -$21.9K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $408.9M | $664.2K | $963.1K | $20.4M | $1.8M | $1.8M | ||||
| Retained Earnings Accumulated Deficit | -$317.8M | -$7.3M | -$6.2M | -$3.5M | -$3.4M | -$3.2M | ||||
| Liabilities Current | $35.7M | $2.6M | $1.9M | $126.7K | $79.1K | $23.3K | ||||
| Liabilities And Stockholders Equity | $484.8M | $197.4M | $195.7M | $192.3M | $189.9M | $187.5M | ||||
| Liabilities | $38.1M | $8.1M | $7.4M | $5.6M | $5.6M | $5.5M | ||||
| Assets | $484.8M | $197.4M | $195.7M | $192.3M | $189.9M | $187.5M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$734.6K | $1.8M | ||||||||
| Temporary Equity Accretion To Redemption Value | $2.1M | $2.0M | $2.4M | $9.4M | ||||||
| Assets Current | $476.0M | $876.8K | $1.2M | $2.0M | $2.1M | $2.1M | ||||
| Accrued Liabilities Current | $1.8M | $119.7K | $126.7K | $79.1K | $23.3K | |||||
| Assets Held In Trust Noncurrent | $196.5M | $194.4M | $192.4M | $190.2M | $187.6M | $185.2M | ||||
| Deferred Underwriting Fee | $5.5M | $5.5M | $5.5M | $5.5M | $5.5M | |||||
| Noncash Accrued Offering Costs Adjustment | $81.0K | |||||||||
| Deferred Offering Costs Paid By Sponsor Through Promissory Note | $139.8K | |||||||||
| Repayments Of Related Party Debt | $209.9K | |||||||||
| Paymentto Acquire Investmentof Cash In Trust Account | $184.0M | |||||||||
| Prepaid Expense And Other Assets Current | $7.5M | $62.5K | ||||||||
| Notes Payable Current | $691.0K | |||||||||
| Marketable Securities Unrealized Gain Loss | -$15.0K | -$140.0K | -$157.0K | $789.0K | -$59.0K | |||||
| Accrued Offering Costs Current | ||||||||||
| Temporary Equity Accretion To Redemption Value Adjustment | $2.6M | $2.4M | $9.4M | |||||||
| Deferred Costs | ||||||||||
| Common Stock Value | $8.0K | $51.00 | ||||||||
| Cash And Cash Equivalents At Carrying Value | $408.7M | $1.8M | ||||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | ||||||||||
| Restricted Cash Noncurrent | $132.0K | |||||||||
| Property Plant And Equipment Net | $827.0K | |||||||||
| Participation Right Liability | $0.00 | $0.00 | $3.8M | $3.1M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $5.9M | $4.4M | |
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $5.9M | $2.3M | |
| Net Cash Provided By Used In Operating Activities | -$113.9M | -$55.0M | |
| Increase Decrease In Prepaid Expense | $3.4M | $1.0M | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $104.7K | $15.0K | |
| Increase Decrease In Shortterm Prepaid Insurance | $249.8K | ||
| Increase Decrease In Longterm Prepaid Insurance | $25.1K | ||
| Proceeds From Issuance Of Private Placement | $373.5M | $0.00 | |
| Net Cash Provided By Used In Investing Activities | $73.3M | -$120.5M | |
| Net Cash Provided By Used In Financing Activities | $383.4M | $206.3M | |
| Proceeds From Saleof Private Placement Shares Netof Underwriting Discounts Paid | 182.2M | ||
| Payments For Repurchase Of Initial Public Offering | $578.6K | ||
| Increase Decrease In Due To Related Parties Current | $67.8K | ||
| Increase Decrease In Participation Liabilities | $725.0K | $564.0K | |
| Proceeds From Sale And Maturity Of Marketable Securities | $157.9M | $31.5M | |
| Proceeds From Payments For Long Term Loans For Related Parties | $0.00 | $2.4M | |
| Proceeds From Partnership Contribution | $0.00 | $1.1M | |
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock | $0.00 | $5.9M | |
| Payments To Acquire Property Plant And Equipment | $606.0K | $49.0K | |
| Payments To Acquire Marketable Securities | $83.9M | $154.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $36.0K | $57.9K | $77.4K | $77.4K | $39.4K | |
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $1.4M | $875.0K | $627.0K | $768.0K | $279.0K | $660.0K |
| Net Cash Provided By Used In Operating Activities | -$734.6K | -$618.0K | ||||
| Increase Decrease In Prepaid Expense | $61.6K | $16.3K | ||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $1.7M | $8.3K | ||||
| Increase Decrease In Shortterm Prepaid Insurance | -$37.3K | $249.8K | ||||
| Increase Decrease In Longterm Prepaid Insurance | -$25.1K | $212.5K | ||||
| Proceeds From Issuance Of Private Placement | $5.1M | |||||
| Net Cash Provided By Used In Investing Activities | -$184.0M | |||||
| Net Cash Provided By Used In Financing Activities | $186.5M | |||||
| Proceeds From Saleof Private Placement Shares Netof Underwriting Discounts Paid | 182.2M | |||||
| Payments For Repurchase Of Initial Public Offering | $578.6K | |||||
| Increase Decrease In Due To Related Parties Current | $19.4K | |||||
| Increase Decrease In Participation Liabilities | ||||||
| Proceeds From Sale And Maturity Of Marketable Securities | ||||||
| Proceeds From Payments For Long Term Loans For Related Parties | ||||||
| Proceeds From Partnership Contribution | ||||||
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock | ||||||
| Payments To Acquire Property Plant And Equipment | ||||||
| Payments To Acquire Marketable Securities |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Preferred Stock Shares Authorized | 10.0M | 0.00 | 5.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Weighted Average Number Of Shares Outstanding Basic | 31.1M | 12.9K | |
| Weighted Average Number Of Diluted Shares Outstanding | 31.1M | 12.9K | |
| Earnings Per Share Diluted | $-4.30 | $-5,756.41 | |
| Earnings Per Share Basic | $-4.30 | $-5,756.41 | |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | |
| Preferred Stock Shares Issued | 0.00 | 0.00 | |
| Common Stock Shares Issued | 80.0M | 28.4K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Preferred Stock Shares Authorized | 10.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Weighted Average Number Of Shares Outstanding Basic | 43.5M | 11.1K | ||||
| Weighted Average Number Of Diluted Shares Outstanding | 43.5M | 11.1K | ||||
| Earnings Per Share Diluted | $-1.03 | $-1,562.18 | ||||
| Earnings Per Share Basic | $-1.03 | $-1,562.18 | ||||
| Preferred Stock Shares Outstanding | 0.00 | |||||
| Preferred Stock Shares Issued | 0.00 | |||||
| Common Stock Shares Issued | 79.2M | 4.2M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Investment Income Interest | |||
| Prepaid Insurance | |||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $22.1K | ||
| Stock Issued During Period Value New Issues | $5.1M | ||
| Additional Paid In Capital | $767.6M | $43.5M | $24.5K |
| Prepaid Taxes | |||
| Longterm Prepaid Insurance | |||
| Interest Income Operating | $11.3M | $6.4M | |
| Income From Transition Services Agreements | $1.2M | $775.0K | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $271.6K | ||
| Formation And Operation Expenses Paid By Sponsor | $26.7K | ||
| Other Significant Noncash Transaction Value Of Consideration Received1 | $0.00 | $3.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|
| Investment Income Interest | $2.1M | $2.0M | $2.6M | $2.4M | $1.2M | ||
| Prepaid Insurance | $150.0K | $212.5K | $249.8K | $249.8K | |||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $22.1K | ||||||
| Stock Issued During Period Value New Issues | $5.1M | ||||||
| Additional Paid In Capital | $764.4M | ||||||
| Prepaid Taxes | $63.8K | $2.2K | $6.3K | ||||
| Longterm Prepaid Insurance | $25.1K | $87.6K | $150.0K | ||||
| Interest Income Operating | $3.4M | $2.5M | |||||
| Income From Transition Services Agreements | $1.0M | $432.0K | |||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $77.4K | $77.4K | $39.4K | ||||
| Formation And Operation Expenses Paid By Sponsor | |||||||
| Other Significant Noncash Transaction Value Of Consideration Received1 |
Most recent annual filing with the SEC: March 5, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.